VKTX - Viking Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
549.93M
Enterprise Value 3
243.08M
Trailing P/E
N/A
Forward P/E 1
-11.89
PEG Ratio (5 yr expected) 1
-0.45
Price/Sales (ttm)
N/A
Price/Book (mrq)
1.94
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
N/A

Trading Information

Stock Price History

Beta (3Y Monthly) 2.29
52-Week Change 3-22.57%
S&P500 52-Week Change 319.31%
52 Week High 311.03
52 Week Low 36.15
50-Day Moving Average 37.20
200-Day Moving Average 37.40

Share Statistics

Avg Vol (3 month) 31.45M
Avg Vol (10 day) 31.52M
Shares Outstanding 572.26M
Float 56.21M
% Held by Insiders 111.03%
% Held by Institutions 168.50%
Shares Short (Nov 15, 2019) 419.05M
Short Ratio (Nov 15, 2019) 415.17
Short % of Float (Nov 15, 2019) 429.62%
Short % of Shares Outstanding (Nov 15, 2019) 426.36%
Shares Short (prior month Oct 15, 2019) 420.65M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-6.46%
Return on Equity (ttm)-8.05%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)-23.57M
Diluted EPS (ttm)-0.33
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)288.07M
Total Cash Per Share (mrq)3.99
Total Debt (mrq)733k
Total Debt/Equity (mrq)0.26
Current Ratio (mrq)46.71
Book Value Per Share (mrq)3.92

Cash Flow Statement

Operating Cash Flow (ttm)-15.69M
Levered Free Cash Flow (ttm)-13.16M